Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case

Background Constitutive activation of HER2-dependent intracellular signalling by HER2 gene amplification or by HER2 mutations has been demonstrated as a mechanism of primary and secondary cancer resistance to cetuximab or panitumumab in preclinical and clinical models of metastatic colorectal cancer (mCRC). Both HER2 Amplification for Colorectal Cancer Enhanced Stratification (HERACLES) cohort A…

Read the full article here

Source: Esmo Open

Categories: Hem/Onc News and Journals

Tags: TDT

Tweets with this article

ESMO Open

Top Cited in ESMO Open Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case ESMO - European Society for Medical Oncology The Daily Tweet #TDT https://t.co/6G56RGC7zg

Targeting HER2-low gastric cancer, summary by Erman Akkus – OncoDaily

Targeting HER2-low gastric cancer, summary by Erman Akkus / A Ooki, Ankara University Faculty of Medicine, Breast Cancer, cancer, Erman Akkus, ESMO Open,

ESMO Open August 29, 2024

HER2-low gastric cancer: is the subgroup targetable?

Therapeutic developments in the targeting of human epidermal growth factor receptor 2 (HER2)-expressing gastric cancer have followed the dramatic success of HER2-expressing breast cancer treatment,…

ESMO Open August 25, 2024

Interstitial lung disease in patients enrolled in early-phase clinical trials: the ILDE study

Interstitial lung disease (ILD) encompasses a heterogeneous group of disorders sharing pathophysiological inflammatory mechanisms, leading to parenchymal distortions. The prevalence of ILD with new cancer…

ESMO Open August 8, 2024

A first-in-human phase I study of a novel MDM2/p53 inhibitor alrizomadlin in advanced solid tumors

The mouse double minute 2 homolog (MDM2) oncogene exerts oncogenic activities in many cancers and represents a potential therapeutic target. This trial evaluated the safety,…

ESMO Open July 16, 2024

Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancer

The characterization and comparison of gene expression and intrinsic subtype (IS) changes induced by neoadjuvant chemotherapy (NACT) and endocrine therapy in hormone receptor-positive (HR+)/human epidermal…

ESMO Open June 30, 2024

HRD testing for advanced high-grade ovarian carcinoma in first line

International guidelines strongly recommend the use of the homologous recombination deficiency (HRD) test in the selection of first-line maintenance therapy for patients with high-grade serous…

ESMO Open June 7, 2024

Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohort

Breast cancer (BC) is the second most common cancer that metastasizes to the brain. Particularly up to half of patients with human epidermal growth factor…

ESMO Open May 8, 2024

Antibody–drug conjugates are active in patients with HER2-positive breast cancer brain metastases: where do we go from here?

In this issue of ESMO Open, Hurvitz and colleagues1 report an exploratory analysis of trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in the subgroup of…

ESMO Open April 24, 2024

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial

DESTINY-Breast03 is a randomized, multicenter, open-label, phase III study of trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients with human epidermal growth factor receptor…

ESMO Open April 24, 2024

The efficacy of sacituzumab govitecan and trastuzumab deruxtecan on stable and active brain metastases in metastatic breast cancer patients—a multicenter real-world analysis

Fifteen to thirty percent of all patients with metastatic breast cancer (MBC) develop brain metastases (BCBMs). Recently, the antibody–drug conjugates (ADCs) sacituzumab govitecan (SG) and…

ESMO Open April 19, 2024

Related Articles